Combination therapies are emerging as a cornerstone of MDS treatment, with synergistic regimens combining HMAs, immunotherapies, and growth factors to improve efficacy and reduce resistance. These multi-drug approaches address the heterogeneity of MDS, which often involves multiple genetic mutations, and are driving market growth as they become standard of care. The combination segment now accounts for 25% of market revenue, up from 10% in 2020, with early trials showing 30% higher complete response rates.

Leading combinations include HMAs paired with immunotherapies. A 2024 study in Leukemia & Lymphoma found that azacitidine + pomalidomide reduced AML progression by 60% in high-risk MDS patients, compared to 40% with single-agent therapy. Another promising regimen is lenalidomide + darbepoetin alfa (a growth factor), which boosts red blood cell production and lowers transfusion needs, appealing to lower-risk MDS patients.

Pharma firms are investing heavily in combo development. [Eli Lilly] recently launched a Phase III trial for its IDH1 inhibitor + HMA regimen, targeting patients with IDH1 mutations. Meanwhile, [Jazz Pharmaceuticals] secured FDA approval for a lenalidomide + azacitidine co-pack, simplifying dosing and improving adherence. These efforts have spurred interest from investors; combination therapy startups raised $AA million in 2023, a 70% jump from 2022.

However, combo therapies face challenges, including increased toxicity and complex dosing schedules. Oncologists report that 20% of patients discontinue combo regimens due to side effects like neutropenia. To address this, firms are exploring dose optimization and biomarker-guided combinations. For businesses tracking this trend, Market Research Future’s MDS Combination Therapies Market Report details regimen efficacy, clinical trial data, and adoption barriers, guiding strategic investments.